The United States authorized remdesivir for emergencies. (Free Press Photo: Hemeroteca PL)
The antiviral drug remdesivir Reduces recovery time in coronavirus sufferers, according to research results published May 22.
The study, conducted by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States, was published by the New England Journal of Medicine.
On May 1, the United States authorized the use in emergency case of remdesivir in hospitals, a measure that Japan also took and that Europe could adopt.
The study found that remdesivir, injected intravenously over 10 days, accelerates the recovery of patients hospitalized for covid-19, compared to the use of a placebo.
The clinical tests were done with more than thousand patients in ten different countries.
On April 29, NIAID Director Anthony Fauci, the visible face of the administration of Donald trump in managing the pandemic, he said that preliminary tests showed that remdesivir had a “clear, significant and positive effect to decrease recovery time.”
However, the study authors indicate that the drug cannot prevent all deaths.
“Given the high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is probably not sufficient,” they indicate.